Menu
Menu
September 02, 2024 ｜Taipei, Taiwan
Taiwan Bio-Manufacturing Corporation (Headquarters: Taipei, Taiwan; CEO: David Chang; hereinafter referred to as “TBMC”) has announced that CBC will invest Taiwan Bio-Manufacturing Corporation (Headquarters: Taipei, Taiwan; CEO: David Chang; hereinafter referred to as “TBMC”) and become one of TBMC’s shareholders. Further, TBMC and CBC have signed a Memorandum of Agreement (MOA) to collaborate on expanding TBMC’s presence in the Japanese market.
Under the term of MOA, CBC will serve as TBMC’s authorized agent for all products including nucleic acid, vaccine, cell therapy, gene therapy and biologics in Japan. This partnership will leverage CBC’s deep market expertise and extensive network to bring TBMC’s innovative and highly-flexible-capacity bioprocessing solutions to Japanese customers. This collaboration will enable TBMC to accelerate business growth in Japan and deliver advanced bioprocessing technologies to a broader market.
Taiwan Bio-Manufacturing Corporation (TBMC), conceived by the Ministry of Economic Affairs and jointly established by the Industrial Technology Research Institute (ITRI) and the Development Center for Biotechnology (DCB), officially commenced operations in May 2023. Dedicated to advancing biomanufacturing capabilities, TBMC partners with National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company. Combining the expertise of National Resilience Inc. and Taiwan’s smart manufacturing capabilities, TBMC is dedicated to developing state-of-the-art solutions for the production of complex medicines, including (i)mRNA drug, (ii)viral vectors, (iii)cell therapy, and (iv)CHO-C protein pharmaceutical platforms.
TBMC operates from two primary manufacturing locations. Two Process Analytical Development Laboratories (PAD Labs; 1,820m2) are situated in the Taipei Bioinnovation Park and Hsinchu Biomedical Science Park. Both are slated for operational readiness and will have expanded operations in new facilities by June 2024 and December 2024, respectively. Meanwhile, the GMP plant (15,000m2) will be housed in the Hsinchu Biomedical Science Park and the facility will be commissioned and ready for GMP operation by the third quarter of 2025.
CBC was founded in 1925 as a trading company dealing mainly in chemical products. As a “creative trading company” with a 100-year history, CBC has developed diverse businesses ranging from the fields of chemicals, resins, and pharmaceuticals to electronics, optical equipment, and agriscience with the aim of providing “health,” “safety,” and “convenience,” which are indispensable for people to lead affluent lives. Recently, in addition to its trading company function, the company has been focusing on the manufacturer business, owning its own plants for manufacturing pharmaceutical intermediates, automobile parts, optical lenses, etc. The group’s total sales, both domestic and international, are approximately 220 billion yen, and the group responds to all needs with a wide variety of items and diverse business styles, while utilizing the group’s networking, information gathering, and collaboration capabilities.
For more information, please visit the website.
